of adults and children or restricted inclusion to insulin pump users. [7] [8] [9] More recently the value of standardizing reports of CGM data in addition to HbA1c has gained momentum, focusing on time in target range results can be invaluable to expedite understanding of the obstacles to improving glucose control. [3] [4] [5] The aim of this study was to demonstrate the equivalence (non-inferiority) of time in range using the flash glucose monitoring system compared to self-monitoring of blood glucose (SMBG) in children and young people (4-17 years) with type 1 diabetes.
| METHODS
This prospective, multicenter, open-label, non-inferiority, single arm treatment study (ClinicalTrials.gov NCT 02821117) was conducted at 10 European diabetes centers (seven in United Kingdom, two in
Republic of Ireland, and one in Germany). Eligible patients were: aged 4 to 17 years with type 1 diabetes for a year or more, on their current insulin regimen for at least 2 months, and performing self-monitoring regularly (equivalent to ≥2 times per day). Patients not included were;
allergic to medical-grade adhesives, currently using FreeStyle Libre or CGM or used in the previous 3 months, pregnant, breast feeding, or receiving oral steroid therapy for any condition. Non-inferiority was confirmed if the lower limit of the two-sided confidence interval (CI) for the mean change in time in range was ≥−1.2 h/d, to correspond to a change of +0.3% (3.3 mmol/mol) HbA1c. 10 Prior to starting the study, independent ethics approval was obtained for all centers and each participant's written informed consent. The study was conducted in compliance with the protocol, International Conference on Harmonisation Guidelines, Good Clinical Practice, and Declaration of Helsinki.
Following consent, screening for eligibility, and enrolment, all participants had baseline HbA1c (local laboratory tested) and physical measurements taken. Subsequently, all participants wore the system in masked mode for the 14-day baseline period and were asked to scan their sensor when performing blood glucose fingerstick tests and at least every 8 hours. Sensor glucose measurements were not visible and glucose management was supported by SMBG, as required, utilizing the reader strip-port (Abbott Diabetes Care, Witney, Oxon, UK).
For the 8-week treatment phase, the system was unmasked and participants utilized sensor glucose data, according to the device labeling, for self-management, including insulin titration ( Figure S1 in Supporting Information). Participants had access to system software for home-use if they wished. 11 No training on interpretation of glucose sensor data was provided. No treatment protocols or insulin titration algorithms were used. In line with standard diabetes care, participants were encouraged to utilize current or historical glucose data to selfmanage their glucose levels. At day 29, glycemic control and sensor data reports (generated at the clinic using system software 11 ) were reviewed with a healthcare professional.
| Outcomes
The primary effectiveness endpoint was the equivalence (non-inferior- Adverse events (including symptomatic hypoglycemia, severe hypoglycemia, 13 and diabetic ketoacidosis) and sensor insertion-site symptoms were monitored throughout the study.
| Statistical analysis
Time in range, other glycemic measures, HbA1c, TDD of insulin, and BMI were considered using a paired t-test. Since the study did demonstrate superiority in the primary endpoint, it is appropriate to switch the hypothesis from non-inferiority to superiority. 14 (Figure 1 ). Time spent above all hyperglycemic thresholds reduced ( Table 2) .
| Glycemic measures
Time spent in glucose >180 mg/dL reduced by −1.2 AE 3. Time spent in hypoglycemia (<70 mg/dL) was unchanged (from
There was a small increase in the number of events (<70 mg/dL) by 0.2 AE 0.6 from 0.8 AE 0.7 to 1.0 AE 0.7 (P = 0.01, Table 2 ).
HbA1c measurements were improved from 7.9 AE 1.0%
(62.9 AE 11.2 mmol/mol) at baseline to 7.5 AE 0.9% (58.5 AE 9.8 mmol/ mol) at 8 weeks, decreasing by −0.4 AE 0.6% (4.4 AE5.9 mmol/mol, [mean AE SD], P < 0.0001).
Mean glucose reduced by −10 AE 30 mg/dL (P = 0.005, Table 2 ).
Glycemic variability improvements were; SD (P = 0.004), high blood glucose index (P = 0.004), and blood glucose risk index (BGRI) (P = 0.005). Change for low blood glucose index did not reach statistical significance (P = 0.06, [ Table 2 ]).
| Insulin use and BMI
Self-reported TDD of insulin (71 participants) increased by 4% Table S1 in Supporting Information]).
BMI is expected to change with age and increased during the study (0.28 AE 0.68 kg/m 2 [mean AE SD], P < 0.001). BMI adjusted for age 15 increased by 0.13 AE 0.40 SDS (P = 0.006).
| Sensor scanning frequency
With unmasked system use, mean daily frequency of SMBG testing immediately reduced from 7.7 AE 2.5 per day (mean AE SD) during baseline to 1.6 AE 1.9 per day during the treatment phase and frequency of sensor scans was 12.9 AE 5.7 per day ( Figure 2 ). Abbreviations: CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injection. Data are n/N (%) or mean (SD).
FIGURE 1 Trial design
System utilization was 91% AE 9 (median 95%) overall, 95% AE 4 (median 97%) in participants aged 4-6 years (n = 13); 93% AE 6 (median 95%), in 7 to 12 year olds (n = 35), and 87% AE 12 (median 89%) in teenagers (n = 23, [ Table S2 in Supporting Information]).
Further analysis of the final 14 days (days 57-70) showed that participants with a higher time in range scanned the sensor more often (P = 0.05) and change in time in range was also positively associated with scanning frequency (P = 0.05).
| Sub-group analysis
Time in range rose in each age group; improving for participants aged 4 to 6 years (P = 0.035) and for 13 to 17 year olds (P = 0.025). The HbA1c reduced in each age group (Table S6 in Supporting Information) with the greatest improvement observed in teenagers (Tables S7 and   S8 in Supporting Information).
| Patient-reported outcomes
The Diabetes Treatment Satisfaction Questionnaire (parent version) score for caregivers (n = 70) improved for overall satisfaction with treatment (P < 0.0001) and perceived diabetes control (P < 0.0001). 
| Insulin dose decision making
During the final 14-day phase, 18 of 23 teenage participants recorded their insulin dose decisions in a diary. Eight teenagers (44%) calculated/decided insulin doses on all (100%) occasions, 16 (89%) on >90% of occasions, and 17 (94%) on >80% of occasions. One (6%)
13-year-old female participant, with a baseline HbA1c of 11.1%
(98 mmol/mol), reported making less than 20% of dosing decisions.
Comparing glycemic measures for decision makers on <80%, 80% to 99%, and 100% of occasions with younger children, there was no difference between these subgroups for time in range, hyperglycemia, and the BGRI. For time in hypoglycemia (<70 mg/dL), there was no difference in the subgroups making 100% (P = 0.89) and those making <80% of decisions (P = 0.56). For the 80% to 99% sub-group, time in hypoglycemia increased by 1.2 h/d compared to younger participants (P = 0.002).
| Adverse events
There were no serious adverse events for severe hypoglycemia, 13 hyperglycemia, or diabetic ketoacidosis. One participant withdrew after experiencing moderate erythema which resolved without treatment and was reported as sensor-wear related; an anticipated device effect. In total, there were 121 adverse events or serious adverse were reported for two participants (gastroenteritis and bruised back; Table S10 in Supporting Information) which were unrelated to the study device or procedure. There were three mild device-related (sensor wear) adverse events (dry flaky skin, dry yellow/white collection, and non-itchy, redness) for three participants (aged 8, 6, and 15 years [Table S11 in Supporting Information]).
Sensor insertion signs and symptoms (n = 96) experienced by 42 participants were associated with sensor insertion (bleeding [27 occurrences], pain [24] , induration [7] , and bruising [4] ) or sensor wear (erythema [23] , itching [5] , rash [5] , and infection [1] , reported as mild, resolved without treatment). See Table S12 Notably, time in range and HbA1c improved without impacting clinical concern on hypoglycemic risk; all clinicians agreed that the sensor glucose reports provided insight into hypoglycemia ( Figure S7 in Supporting Information). To the best of our knowledge, improved time in the range associated with reduced HbA1c was last reported in the pediatric population using CGM in 2007. 16 More specifically, HbA1c reduction and CGM use in this population has been not consistently observed. 7, 18, 21, 22 The observed 0.4% (4.4 AE 5.9 mmol/mol) HbA1c improvement is substantial for this short study duration, comparable to the 0.6% reduction reported for standard CGM use for 13 weeks in a similar population 23 and to sensor-augmented pump therapy use in children for 6 or 12 months improving HbA1c levels by 0.46% 8 and 0.50%, 24 respectively. The observed HbA1c improvement across all ages was irrespective of insulin administration method and may suggest that access to current and retrospective glycemic information should be a priority for standard glucose management in children with diabetes.
Glycemic benefit from sensor-augmented insulin pump technology 25 and CGM use in children is strongly associated with consistent sensor use. 7, 9, 22 Despite technological advances, sensor use declines over time, 26 particularly in children <10 years 21, 27 and teenagers. 6, 18, 25 In the present study, scanning frequency, almost double compared with SMBG frequency at baseline, together with high system utilization across all the age groups, suggests confidence in sensor results. In a population noted as susceptible to reduced concordance with sensor wear, sustained sensor use even over this short time period is notable. 9, 28 In addition, higher system utilization and improved treatment satisfaction were observed although positive patient-reported outcome measures may not be predictive of sensor use. 9 Our findings support reports for CGM use in children 9, 29 and equally contrast to others showing increased parental and/or user satisfaction despite low rates of sensor adherence. 9, 21, 26, 29 The improvement in HbA1c is especially notable in the teenage participants as a reduction may not always be achieved with SAP technology. 25 Teenagers can confound expectations of improved glucose from technology use with high attrition rates from trials 17,29 and a weaker association of sensor use with improved glycemic control. 22 Commonly, teens favor accessing current glucose results discreetly and may not share assumed benefits, such as the streaming of glucose data, 30 seeing it as disruptive, 31 visually obvious, and differentiating them from their peers. 32 These issues may explain the high sensor system utility observed in this sub-group which add to findings in flash sensor use for young adults. 33 Glycemic improvements for teenagers making all/most insulin dose decisions were broadly similar to those observed for younger children. The reasons for increased time spent in hypoglycemia in nine teenagers nearing full independence (80%-99% insulin decisions), who also showed the biggest improvement in hyperglycemia, are not clear.
Sensor-wear adverse events were similar to the reported prevalence in this population for sensor use over 2 weeks. 34 Symptoms were primarily mild and do not appear to have impacted on the high level of device acceptability, as demonstrated by the user questionnaire results which support findings from a shorter study. 34 The strength of the study was its reflection of the real-world in demonstrating safe home-use of the system without device training or a mandated insulin adjustment algorithm. Limitations include shortterm use of the system in a cohort with reasonable glycemic control for this population, relatively small participant numbers in each age sub-group and no control group for comparison. The study duration was designed to evaluate the effect of starting use of FreeStyle Libre, allowing time for a clinical review of the sensor glucose data generated and for the outcome of that review to have an effect on outcomes. The study was of sufficient duration to evaluate the effect on glycemic control. Whether further improvement, maintenance, or weakening of glycemic benefit would occur with longer device use is unknown. No adjustment was made for multiple testing of secondary endpoints and as many of these are highly inter-related they should not be considered in isolation. Future studies over a longer period with a larger cohort and control arm are now required to further assess the long-term impact of flash technology in this population.
In summary, non-inferiority, and superiority, of flash glucose monitoring over self-monitoring of blood glucose for glycemic control were demonstrated in this short-term, single arm study. Use of flash glucose technology in children and young people with type 1 diabetes using insulin pump or multiple injection therapy resulted in improved time in range, reduced HbA1c, and better treatment satisfaction.
